Researcher’s Profile

Robert S. Brown Jr., MD, MPH

Americas Top Doctor : 
Medical Director, Transplant Initiative, Morgan Stanley Children's Hospital of NewYork-Presbyterian
Director, Center for Liver Disease and Transplantation

1) Determinants of the outcome of orthotopic liver transplantation (OLT) OLT is a highly successful therapy that has become a standard treatment for many forms of end stage liver disease. Since it is quite expensive, maximizing the benefit while decreasing the cost is of paramount importance. We are currently investigating the predictors of post-transplant outcomes in particular the impact of pre-transplant therapies like TIPS on cost and pre and post-transplant morbidity and mortality. 2) Quality of Life in Chronic Liver Disease Chronic liver disease greatly impairs patients ability to function both physically and within societal and family roles. The impact of liver disease on quality of life has not been extensively investigated. We are utilizing liver disease-specific quality of life instruments and to analyze the impact of liver disease and its treatment on patients with liver disease, those undergoing treatment for Hepatitis C and potential donor and recipients of living donor liver transplants. 3) Artificial Liver Support There is no currently viable support system for patients whose liver is failing analogous to dialysis for renal failure. Several devices have been proposed for this problem. These include those with living liver cells (bioartificial liver devices) and those without liver cells. We are actively involved in trials of both bioartificial as well as dialysis-based artificial liver support systems for acute and chronic liver failure. 4) Clinical Trials in Liver Disease and Transplantation I am involved in many active clinical trials in Liver disease. In addition to studies of artificial liver support, we have several active drug protocols for Hepatitis B and C. We are also currently participating in several multi-center studies to investigate anti-viral prophylaxis strategies as well as various immunosuppressive agents following liver transplantation.


New Data from Largest U.S. Hepatitis C Trial Provide Insights Into Optimizing Treatment for Patient Populations Traditionally Considered Difficult to Treat
Brown R, Jacobson I. Tenofovir Disoproxil Fumarate in Patients with Lamivudine-Resistant Chronic Hepatitis B Virus Infection: A Review. Am Jour of Gastoenterol (submitted)
Sher L, Jennings L, Rudich S, Netto G, Teperman L, Kinkhabwala M, Brown RS Jr., Pomfret E, Klintmalm G, HCV-3 Study Group. The Impact of Live Donor Liver Transplantation on Hepatitis C Recurrence: The HCV 3 Trial Experience. (In oress)
Liaw Y, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY, Myers RP, Brown RS Jr., Jeffers L, Tsai N, Bialkowska J, Tang S, Beebe S, Cooney E. Efficacy and Safety of Entecavir versus Adefovir in Chronic Hepatitis B Patients with Hepatic Decompensation: A Randomized Open-Label Study (submitted)
Trotter JF, Gillespie BW, Terrault NA, Abecassis MM, Merion RM, Brown RS Jr, Olthoff KM, Hayashi PH, Berg CL, Fisher RA, Everhart JE, and the Adult-to-Adult Living Donor Liver Transplantation Cohort Study Group. Laboratory Test Results After Living Liver Donation in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study. Liver Transpl 17:409-417, 2011